hyp
New 2-in-1 Valturna outperforms Diovan
October 1, 2009Sales and Marketing Diovan, Novartis, Tekturna, cv, hyp, hypertension
Novartis has gained US approval for a combination of its blockbuster blood pressure drug Diovan and its follow-up product Tekturna/Rasilez.Valturna …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
